These data provide pre-clinical evidence in GBM xenografts that the EFNA5 agonist, doxazosin, is effective against early stages of GBM derived from GIC with a BMI1high/EFNA5low molecular signature. This evidence concerns the gene EFNA5 and glioblastoma.